title: Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
authors.affiliation: Regeneron Pharmaceuticals, Tarrytown, NY, USA.
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Holash
authors.forename: Gavin
authors.initials: G
authors.lastname: Thurston
authors.forename: John S
authors.initials: JS
authors.lastname: Rudge
authors.forename: George D
authors.initials: GD
authors.lastname: Yancopoulos
authors.forename: Alex A
authors.initials: AA
authors.lastname: Adjei
authors.forename: Gabriele
authors.initials: G
authors.lastname: Bergers
authors.forename: Bronislaw
authors.initials: B
authors.lastname: Pytowski
authors.forename: Mark
authors.initials: M
authors.lastname: Pegram
authors.forename: Michael S
authors.initials: MS
authors.lastname: Gordon
mesh_terms: D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020286:Pericytes / Q000187:drug effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D017978:Receptors, Growth Factor; D042582:Vascular Endothelial Growth Factor C; D040321:Vascular Endothelial Growth Factor Receptor-3